Bone disease in multiple myeloma: pathophysiology and management

Area of Science:

• Oncology
• Orthopedics
• Pathophysiology

Background:

• Myeloma bone disease (MBD) is a frequent and severe complication of multiple myeloma (MM).
• Over 80% of MM patients experience destructive bone lesions, impacting quality of life and increasing healthcare costs.
• Bone destruction and impaired bone formation are key to MBD development.

Purpose of the Study:

• To provide a comprehensive overview of the pathophysiology of MBD.
• To summarize current and emerging management strategies for MBD.
• To highlight key molecular pathways involved in MBD pathogenesis.

Main Methods:

• Literature review of MBD pathophysiology and treatment.
• Analysis of molecular mechanisms including RANKL/OPG and Wnt/DKK1 pathways.
• Synthesis of information on therapeutic interventions.

Main Results:

• Identified key molecular pathways (RANKL/OPG, Wnt/DKK1) in MBD.
• Detailed the significant impact of MBD on patient morbidity and healthcare costs.
• Outlined diverse treatment modalities including novel agents, bisphosphonates, and supportive care.

Conclusions:

• MBD is a major cause of morbidity in MM patients, driven by complex pathophysiological mechanisms.
• Effective management requires a multi-faceted approach combining systemic therapies, bone-targeting agents, and interventional procedures.
• Further research into MBD pathogenesis may yield improved therapeutic strategies.